Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Treace Medical Concepts (TMCI) EBITDA (2020 - 2025)

Treace Medical Concepts (TMCI) has disclosed EBITDA for 6 consecutive years, with -$9.4 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, EBITDA fell 1480.67% year-over-year to -$9.4 million, compared with a TTM value of -$59.0 million through Dec 2025, down 5.77%, and an annual FY2025 reading of -$59.0 million, down 5.77% over the prior year.
  • EBITDA was -$9.4 million for Q4 2025 at Treace Medical Concepts, up from -$16.3 million in the prior quarter.
  • Across five years, EBITDA topped out at -$595000.0 in Q4 2024 and bottomed at -$21.3 million in Q2 2024.
  • Average EBITDA over 5 years is -$11.2 million, with a median of -$12.3 million recorded in 2022.
  • The sharpest move saw EBITDA crashed 8566.67% in 2021, then skyrocketed 90.03% in 2024.
  • Year by year, EBITDA stood at -$5.6 million in 2021, then grew by 20.69% to -$4.4 million in 2022, then plummeted by 34.49% to -$6.0 million in 2023, then surged by 90.03% to -$595000.0 in 2024, then crashed by 1480.67% to -$9.4 million in 2025.
  • Business Quant data shows EBITDA for TMCI at -$9.4 million in Q4 2025, -$16.3 million in Q3 2025, and -$17.4 million in Q2 2025.